Table 3.
Summary of efficacy and reason for treatment discontinuation by patient
| Patient number | Best overall response | PFS, months | Reason for treatment discontinuation | ||
|---|---|---|---|---|---|
| Paclitaxel | Cisplatin | Bevacizumab | |||
| 1 | PR | 5.6 | Grade 1 peripheral sensory neuropathy | Grade 1 fatigue | Disease progression |
| 2 | PR | 5.4a | Grade 2 peripheral sensory neuropathy | Grade 1 fatigue | – |
| 3 | PR | 4.8a | – | – | – |
| 4 | PR | 7.6a | Grade 2 peripheral sensory neuropathy | Grade 2 blood creatinine increased | – |
| 5 | CR | 5.9a | Grade 2 malaise, grade 2 decreased appetite | Grade 2 malaise, grade 2 decreased appetite | – |
| 6 | SD | 7.4a | – | – | – |
| 7 | PR | 5.8a | Grade 1 peripheral neuropathy | Grade 1 nausea | – |
PFS, progression-free survival; PR, partial response; CR, complete response; SD, stable disease.
aCensored observation, treatment ongoing.